SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer - Quaterly Results

28 Oct 2024 Evaluate
The quarter ended September 2024 witnessed marginal change in the total revenue. The figure for the mentioned quarter is pegged at Rs. 5885.90 millions.Net profit stood at Rs. 1583.50  millions  compared to Rs. 1489.60 millions in the corresponding previous quarter,high by 6.30%.OP of the company witnessed a marginal growth to 2323.20 millions from 2186.80 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 5885.90 5752.10 2.33 11514.50 11065.70 4.06 21931.70 24247.60 -9.55
Other Income 430.70 360.70 19.41 849.10 695.30 22.12 1805.10 1010.50 78.63
PBIDT 2323.20 2186.80 6.24 4516.50 3628.50 24.47 8158.10 9099.10 -10.34
Interest 21.00 27.30 -23.08 42.10 56.00 -24.82 154.10 133.90 15.09
PBDT 2302.20 2159.50 6.61 4474.40 3572.50 25.25 8083.50 9295.20 -13.04
Depreciation 149.90 154.30 -2.85 295.90 309.80 -4.49 622.80 1055.10 -40.97
PBT 2152.30 2005.20 7.34 4178.50 3262.70 28.07 7460.70 8240.10 -9.46
TAX 568.80 515.60 10.32 1087.90 837.80 29.85 1947.40 2000.80 -2.67
Deferred Tax -30.10 42.20 -171.33 -61.50 30.10 -304.32 361.10 -519.10 -169.56
PAT 1583.50 1489.60 6.30 3090.60 2424.90 27.45 5513.30 6239.30 -11.64
Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00
PBIDTM(%) 39.47 38.02 3.82 39.22 32.79 19.62 37.20 37.53 -0.87

Pfizer Share Price

4828.35 17.30 (0.36%)
11-May-2026 09:26 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.10
Dr. Reddys Lab 1279.30
Cipla 1342.10
Zydus Lifesciences 937.00
Lupin 2292.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×